- COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
-
Compounds and compositions useful for treating disorders related to Kit are described herein.
- -
-
Paragraph 0183-0184
(2016/04/26)
-
- NON-SYSTEMIC TGR5 AGONISTS
-
Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.
- -
-
Page/Page column 146
(2013/07/05)
-
- COFERONS AND METHODS OF MAKING AND USING THEM
-
The present invention is directed to a monomer useful in preparing therapeutic compounds. The monomer includes one or more pharmacophores which potentially binds to a target molecule with a dissociation constant of less than 300 μM and a linker element connected to the pharmacophore. The linker element has a molecular weight less than 500 daltons, is connected, directly or indirectly through a connector, to the pharmacophore.
- -
-
Page/Page column 246-247
(2012/12/13)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 60; 71
(2011/04/26)
-
- AMINOGLYCOSIDE DERIVATIVES
-
The present invention relates to antimicrobial and antibiotic aminoglycoside derivatives. The compounds of the present application have the following chemical structures. The invention also relates to compositions, methods of preparation and methods of treatment of bacterial infections using the above aminoglycoside derivative.
- -
-
Page/Page column 49; 50
(2011/12/02)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 73-74
(2011/04/26)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds having antibacterial activity are disclosed. The compounds have one of the following structures (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3 and Z1 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 98
(2011/04/26)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Ql, Q2, Rl, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 60
(2010/04/28)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) or (II): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 103-104
(2010/12/17)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 59-60
(2010/04/28)
-
- ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
-
Compounds of structure (I): having antibacterial activity are disclosed, including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q3, R8 and R9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
- -
-
Page/Page column 150
(2009/06/27)
-
- ANTIBACTERIAL 1,4,5-SUBSTITUTED AMINOGLYCOSIDE ANALOGS
-
The present invention is directed to analogs of aminoglycoside compounds as well as their preparation and use as prophylactic or therapeutics against microbial infection.
- -
-
-
- METHODS OF USING MEK INHIBITORS
-
The present invention provides methods of treating cancer by administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.
- -
-
Page/Page column 384-385
(2008/12/06)
-
- METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS
-
A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.
- -
-
Page/Page column 232-233
(2008/12/04)
-